Skip Navigation


NDT Advance Access originally published online on June 7, 2007
Nephrology Dialysis Transplantation 2007 22(9):2701-2704; doi:10.1093/ndt/gfm353
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/9/2701    most recent
gfm353v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morath, C.
Right arrow Articles by Schwenger, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morath, C.
Right arrow Articles by Schwenger, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading

Christian Morath1, Jeanne Sis1, Gertrud M. Haensch2, Martin Zeier1, Konrad Andrassy1 and Vedat Schwenger1

1Department of Nephrology and 2Department of Immunology, University of Heidelberg, Heidelberg, Germany

Correspondence and offprint requests to: Dr Christian Morath, Department of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg. Email: christian_morath{at}med.uni-heidelberg.de



  Abstract

Background. Procalcitonin (PCT) is routinely measured to differentiate autoimmune disorders from infection. There are reports, however, where PCT is high in the absence of infection, i.e. in vasculitis. To investigate the value of PCT in Goodpasture's syndrome, we reviewed the charts of patients with Goodpasture's syndrome who were treated from 1996 to 2006.

Methods. PCT (normal range <0.5 ng/ml) was measured with an immunoluminometric assay, C-reactive protein (CRP; normal range <5 mg/l) with nephelometry. Anti-glomerular basement membrane antibodies (normal range <1:10) were measured with ELISA.

Results. During the last 10 years we diagnosed seven patients with Goodpasture's syndrome. Six out of seven patients had biopsy proven crescentic and necrotizing glomerulonephritis. Five patients had a severe manifestation with pulmonary involvement (n = 3) and/or severe renal insufficiency (n = 4). Mean CRP levels were 145.7 mg/l, mean PCT levels were 34.1 ng/ml. Therapy consisted of plasmapheresis (n = 3), pulse cyclophosphamide therapy (n = 4) and glucocorticoids (n = 6). Remarkably, all patients with elevated PCT levels had life-threatening disease (n = 4) and remained dialysis-dependent (as compared to with only one out of three patients with normal PCT). In two out of five patients with severe Goodpasture's syndrome, PCT levels remained high. After thorough exclusion of infection, resumption of high dose glucocorticoids normalized PCT and CRP levels.

Conclusions. The measurement of PCT as a marker of infection in patients with Goodpasture's syndrome is misleading. High PCT values might rather point to a severe form of Goodpasture's syndrome with a more unfavourable prognosis. However, further studies with larger patient numbers are needed to prove this hypothesis.

Keywords: Goodpasture's syndrome; infection; inflammation; procalcitonin

Received for publication: 29.12.06
Accepted in revised form: 8. 5.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.